This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial facts on this page are limited to the ClinicalTrials.gov record.
1. Trial at a Glance
SELECT was a completed, multicenter, randomized, double-blind, placebo-controlled phase 3 trial evaluating lenvatinib in participants with 131I-refractory differentiated thyroid cancer. The ClinicalTrials.gov record identifies progression-free survival as the single registered primary endpoint and report a formal hazard-ratio analysis comparing lenvatinib 24 mg with placebo.
| Feature | SELECT |
|---|---|
| Trial name | SELECT |
| Brief title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) |
| Phase | Phase 3 |
| Condition | Thyroid Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Triple |
| Primary purpose | Treatment |
| Enrollment | 392 |
| Registered primary endpoints | 1 |
| Primary endpoint type | Time-to-event |
| Results posted | Yes |
| Statistical analyses posted | 1 |
| Effect measure | Hazard ratio; reported as Cox Proportional Hazard |
| Hypothesis type | Superiority |
| ClinicalTrials.gov | NCT01321554 |
| Lead sponsor | Eisai Inc. |
2. Clinical Question
The primary statistical question was whether lenvatinib 24 mg produced a different time-to-progression-or-death profile from placebo in participants with 131I-refractory differentiated thyroid cancer, under a prespecified superiority framework.
Population
Participants with 131I-refractory differentiated thyroid cancer, as described by the trial's brief title and registered condition.
Intervention
Lenvatinib 24 mg in the Randomization Phase comparison reported in the statistical analysis.
Comparator
Placebo in the Randomization Phase comparison reported in the statistical analysis.
Primary question
Does lenvatinib improve progression-free survival relative to placebo?
3. Trial Design
Lenvatinib 24 mg
- Randomization Phase treatment group.
- Included in the posted primary PFS comparison.
- Serious adverse events: 171 affected of 261 at risk.
Placebo
- Randomization Phase comparator group.
- Included in the posted primary PFS comparison.
- Serious adverse events: 31 affected of 131 at risk.
4. Trial Timing and Registry Status
Trial start
The registry profile gives March 17, 2011 as the study start date.
Primary completion
The registry profile gives November 15, 2013 as the primary completion date.
Current registry status in the ClinicalTrials.gov record
The trial is classified as completed, with results posted on ClinicalTrials.gov.
5. Primary Endpoint
| Endpoint | Registered definition / time frame | Statistical information posted |
|---|---|---|
| Progression Free Survival (PFS) | Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff. | Cox Proportional Hazard; hazard ratio; full analysis set / Intent-to-Treat Analysis Set. |
6. Analysis Population
The posted primary analysis used the full analysis set (Intent-to-Treat Analysis Set), which included all randomized participants.
| Population | Definition in registry-reported analysis | Role |
|---|---|---|
| Full analysis set / ITT | Included all randomized participants. | Primary PFS efficacy analysis. |
This distinction is statistically important. An intention-to-treat analysis preserves the randomized comparison by retaining participants according to their randomized assignment rather than redefining treatment groups based on subsequent treatment exposure. For a randomized superiority comparison, that protects the causal interpretation provided by randomization, subject to the usual assumptions and limitations of the trial design and endpoint analysis.
7. Primary PFS Result
The ClinicalTrials.gov statistical analysis compares Randomization Phase lenvatinib 24 mg with Randomization Phase placebo for progression-free survival. The effect measure is reported as a Cox proportional-hazard measure and normalized as a hazard ratio.
Hazard ratio for progression or death
99% two-sided CI: 0.14–0.31
Superiority hypothesis; analysis population: full analysis set / Intent-to-Treat Analysis Set.
| Endpoint | Lenvatinib 24 mg | Placebo | Effect estimate |
|---|---|---|---|
| Progression Free Survival | Randomization Phase | Randomization Phase | HR 0.21 99% two-sided CI 0.14–0.31 |
What the estimate means: A hazard ratio of 0.21 means that, under the fitted time-to-event model, the estimated instantaneous rate of the PFS event was approximately 21% as high in the lenvatinib 24 mg group as in the placebo group over the analyzed follow-up. Equivalently, this corresponds to an estimated 79% lower instantaneous hazard for the lenvatinib group relative to placebo.
What it does not mean: HR 0.21 does not mean that 21% of patients experienced progression, that 79% of patients were progression-free, or that every individual patient's probability of progression was reduced by exactly 79%. A hazard ratio is a relative model-based measure of event rates over time.
What the confidence interval says: The 99% two-sided confidence interval of 0.14–0.31 quantifies uncertainty around the estimated hazard ratio under the statistical model and sampling framework. It indicates that the point estimate is not the only plausible value; the interval provides a range of parameter values compatible with the specified confidence procedure.
Why the p-value is not discussed as a number: The ClinicalTrials.gov record does not report a p-value. It therefore would be inappropriate to insert one from another source or infer one from the confidence interval. In general, a p-value addresses evidence against a null hypothesis; it does not measure the magnitude or clinical importance of an effect.
Important modeling caution: The reported effect measure is based on a Cox proportional-hazards framework. Interpretation of a single hazard ratio is most straightforward when the proportional-hazards representation is reasonable over the relevant follow-up. The ClinicalTrials.gov record does not report a formal proportional-hazards diagnostic, so this page does not make such a diagnostic claim.
Censoring matters: PFS is a time-to-event endpoint and can involve censored observations. The hazard-ratio estimate therefore incorporates both observed events and the available follow-up information rather than simply comparing proportions with progression.
8. Statistical Methodology
Time-to-event analysis
PFS is fundamentally different from a simple binary endpoint because the analysis uses both whether an event occurred and the timing of that event. Participants who have not experienced progression or death by the relevant observation point can contribute censored follow-up information.
The survival function represents the probability that the event time T exceeds time t. For PFS, the event is the first qualifying disease progression or death.
Kaplan-Meier estimation
For a time-to-event endpoint such as PFS, Kaplan-Meier estimation is a standard nonparametric way to describe the event-time distribution while accounting for right censoring. It produces an estimated probability of remaining event-free over time.
Here, di is the number of events at event time ti, and ni is the number at risk immediately before that time.
Cox proportional-hazards model
The posted effect measure is explicitly reported as a Cox Proportional Hazard and normalized as a hazard ratio. The Cox model expresses the hazard for an individual or treatment group relative to a baseline hazard through a multiplicative treatment effect.
For a binary treatment indicator, exp(β) corresponds to the hazard ratio comparing the treatment group with the reference group under the fitted model.
Intention-to-treat analysis
The registry-reported analysis specifies that the full analysis set / Intent-to-Treat Analysis Set included all randomized participants. This is important because treatment assignment is determined before post-randomization outcomes occur. Keeping participants associated with their randomized assignment helps preserve the comparability created by randomization.
Superiority testing
The hypothesis type is registered as superiority. In a superiority framework, the statistical question is whether the treatment effect differs from the comparator in the favorable direction under the prespecified hypothesis-testing framework. The ClinicalTrials.gov record is an estimated hazard ratio of 0.21, with a 99% two-sided confidence interval of 0.14–0.31.
Blinded independent imaging review
The registry-reported PFS definition states that progression was determined by blinded independent imaging review using RECIST 1.1 during the double-blind treatment period. Blinding of outcome assessment can reduce the opportunity for knowledge of treatment assignment to influence the classification of radiographic progression.
9. Statistical Methods Explained
Why is PFS analyzed as a time-to-event endpoint?
Because PFS incorporates the time from randomization until progression or death, a participant who remains event-free for longer contributes different information from one who experiences an event early. Time-to-event methods also allow censored participants to contribute their available follow-up without pretending that an unobserved event occurred at a particular time.
What does a hazard ratio of 0.21 mean?
Under the fitted Cox model, the estimated instantaneous event rate for the lenvatinib 24 mg group was about 21% of the corresponding rate for placebo. The complement, 1 − 0.21 = 0.79, gives the directly derived statement that the estimated hazard was about 79% lower. Neither statement is an absolute probability of remaining progression-free.
Why is the confidence interval 99% rather than 95%?
The registry-reported analysis explicitly reports a 99% two-sided confidence interval. A confidence interval describes uncertainty around the estimated parameter under its specified confidence procedure. The choice of confidence level changes the width of the interval; it does not change the point estimate itself.
Why is a p-value not enough to describe the treatment effect?
A p-value is designed to quantify evidence against a specified null hypothesis under a statistical model. It does not describe how large an effect is. Here, the effect magnitude is conveyed by the hazard ratio of 0.21, while the 99% confidence interval of 0.14–0.31 conveys precision. The ClinicalTrials.gov record does not provide a numerical p-value.
Why does the ITT population matter?
Analyzing all randomized participants according to the randomized comparison maintains the treatment groups created by randomization. This reduces the risk that post-randomization treatment behavior selectively changes the groups being compared. It does not eliminate missing-data, censoring, adherence, or other sources of potential bias.
Why does blinding matter for PFS?
The endpoint depends on identifying disease progression from imaging. The registry-reported definition states that progression was determined by blinded independent imaging review. Blinding can reduce the possibility that knowledge of treatment assignment influences assessment of whether radiographic criteria for progression have been met.
What is the difference between a hazard ratio and a risk ratio?
A hazard ratio compares modeled instantaneous event rates over time. A risk ratio compares cumulative probabilities of an event over a specified period. They are therefore not interchangeable. A hazard ratio of 0.21 should not be rewritten as a 0.21 risk ratio without an appropriate time-specific risk analysis.
10. Confidence Interval: Reading the 99% CI
The posted hazard-ratio estimate is 0.21, while the 99% two-sided confidence interval extends from 0.14 to 0.31. This interval is important because the point estimate alone can give a false impression of certainty.
All values in the reported interval are below 1.00. For a hazard-ratio comparison in which values below 1 favor lenvatinib relative to placebo, the entire registry-reported 99% interval is on the treatment-favoring side of the null value. That is a descriptive interpretation of the reported interval; it should not be converted into an unreported p-value.
11. Safety Results
The ClinicalTrials.gov record reports serious adverse events by treatment group and risk set. These figures are distinct from the primary PFS analysis and should be interpreted as safety-event counts rather than efficacy outcomes.
| Period / group | Serious adverse events affected | At risk |
|---|---|---|
| Randomization Phase: Lenvatinib 24 mg | 171 | 261 |
| Randomization Phase: Placebo | 31 | 131 |
| OOL, Treatment Period: Lenvatinib 24 mg | 62 | 85 |
| OOL, Treatment Period: Lenvatinib 20 mg | 16 | 30 |
The two Randomization Phase rows correspond to the same groups used in the posted primary PFS comparison. The OOL, Treatment Period rows are reported separately in the ClinicalTrials.gov record and should not be combined with the Randomization Phase safety figures as though they represented the same analysis population.
12. Safety and Efficacy Use Different Statistical Questions
Efficacy question
PFS asks when the first qualifying progression or death occurred after randomization. The posted analysis uses a time-to-event hazard ratio.
Safety question
Serious adverse-event reporting describes affected participants within specified treatment-period risk sets.
Why populations matter
The efficacy analysis explicitly uses all randomized participants. Safety rows are presented with their own affected and at-risk counts.
Why the measures differ
A hazard ratio and an affected/at-risk count answer different questions and should not be treated as interchangeable measures of treatment effect.
13. What Is and Is Not Reported in the Supplied Analysis
The ClinicalTrials.gov record contains one formal statistical analysis: the primary PFS comparison between Randomization Phase lenvatinib 24 mg and placebo. Four outcome measures are reported in the registry profile, but the ClinicalTrials.gov record does not provide detailed statistical analyses for additional endpoints.
| Item | Supplied information |
|---|---|
| Primary endpoint | Progression Free Survival (PFS) |
| Primary endpoint type | Time-to-event |
| Formal statistical analysis | Yes |
| Number of statistical analyses reported | 1 |
| Analysis population | Full analysis set / Intent-to-Treat Analysis Set; all randomized participants |
| Comparison | Randomization Phase: Lenvatinib 24 mg vs Randomization Phase: Placebo |
| Effect measure | Hazard ratio; reported as Cox Proportional Hazard |
| Estimate | 0.21 |
| Confidence interval | 99% two-sided: 0.14–0.31 |
| p-value | Not reported in the registry-reported statistical analysis |
| Secondary efficacy estimates | Not reported in the statistical analysis |
This distinction is deliberate. A complete statistical analysis should not fill gaps in a registry record with numbers from memory or from a different source when the requested data rules restrict the numerical evidence to the ClinicalTrials.gov record.
14. Design Topics Not Supported by the Supplied Data
Several statistical design features commonly discussed for phase 3 trials are not described in the registry-reported SELECT data. They therefore cannot be characterized here as features of this trial.
| Design topic | What can be stated from the ClinicalTrials.gov record |
|---|---|
| Non-inferiority margin | Not reported; the registered hypothesis type is superiority. |
| Crossover | Not reported. |
| Factorial design | Not reported; the design model is parallel. |
| Multiplicity strategy | Not reported. |
| Interim analysis | Not reported. |
| Missing-data or imputation strategy | Not reported. |
| Stratification factors | Not reported. |
| Bayesian methods | Not reported. |
15. Interpreting the Primary Result as a Statistical Story
The SELECT primary analysis can be understood as a sequence of linked statistical decisions rather than as a single number.
First, randomization establishes the comparison framework. Second, PFS records the timing of the first qualifying event. Third, time-to-event methods accommodate censoring. Fourth, the Cox model summarizes the relative event rate through a hazard ratio. Finally, the confidence interval communicates uncertainty around that estimate. The resulting HR of 0.21 is therefore best understood as the output of the entire analysis framework rather than as a simple percentage difference between two groups.
Randomization answers: who is being compared?
PFS answers: what event and time are being measured?
Kaplan-Meier answers: how does the event-free distribution evolve over time?
Cox regression answers: what relative hazard summarizes the treatment comparison?
The confidence interval answers: how uncertain is the estimated hazard ratio?
16. Limitations and Interpretation Issues
- Registry scope: the numerical analysis in the ClinicalTrials.gov record contains one formal statistical comparison, so additional efficacy conclusions cannot be constructed from the four posted outcome measures alone.
- No p-value reported: the primary analysis provides a hazard ratio and 99% confidence interval but no numerical p-value in the ClinicalTrials.gov record.
- Hazard-ratio interpretation: the Cox proportional-hazards framework summarizes a relative event-rate relationship; it is not an absolute risk difference or risk ratio.
- Proportional-hazards assumption: the ClinicalTrials.gov record identifies a Cox proportional-hazard effect measure but do not provide a diagnostic confirming the proportional-hazards assumption.
- Censoring: PFS analysis depends on how event-free participants are censored. The ClinicalTrials.gov recordset does not describe the detailed censoring rules beyond the registered endpoint framework.
- Four-arm structure: the registry profile lists four arms, while the registry-reported formal statistical analysis reports only the lenvatinib 24 mg versus placebo Randomization Phase comparison.
- Safety populations: the serious-adverse-event figures use specified risk sets and treatment periods. They should not be interpreted as though all four rows represented one homogeneous analysis population.
- Unreported design features: no conclusions can be drawn from the ClinicalTrials.gov record about interim monitoring, multiplicity adjustment, missing-data methods, stratification, crossover, or Bayesian methods.
17. Why This Trial Matters Statistically
SELECT is a useful teaching case because the registry analysis illustrates a classic randomized time-to-event framework while also showing why a statistical result must be read in context.
| Concept | How it appears in SELECT |
|---|---|
| Randomization | The trial uses randomized allocation. |
| Blinding | The registry classifies the trial as triple-masked and placebo-controlled. |
| Parallel design | The design model is parallel. |
| ITT analysis | The full analysis set included all randomized participants. |
| Time-to-event endpoint | PFS measures time from randomization to progression or death. |
| RECIST assessment | The registry-reported PFS definition uses RECIST 1.1 and blinded independent imaging review. |
| Cox model | The posted effect measure is reported as Cox Proportional Hazard. |
| Hazard ratio | The reported PFS estimate is HR 0.21. |
| Confidence interval | The estimate has a 99% two-sided CI of 0.14–0.31. |
| Superiority | The registered hypothesis type is superiority. |
| Safety analysis | Serious adverse events are reported by treatment period and risk set. |
18. Statistical Concepts in This Trial
Learn more about the methods used in this trial:
19. Related Statistical Calculators
20. Sources
- ClinicalTrials.gov: SELECT, NCT01321554. Official registry record and the source of the trial data used for this analysis.
- PubMed: PMID 33637020.
- PubMed: PMID 33611104.
- PubMed: PMID 30471649.
- PubMed: PMID 28237867.
- PubMed: PMID 27548104.
Continue with the underlying statistical methods
Explore the concepts that connect randomized clinical-trial design with survival analysis, hazard ratios, confidence intervals, and intention-to-treat analysis.
21. Record Summary
SELECT provides a clear example of how a randomized phase 3 trial can translate a time-to-event endpoint into a model-based treatment-effect estimate. The registry-reported primary analysis uses the full analysis set / Intent-to-Treat Analysis Set, includes all randomized participants, compares Randomization Phase lenvatinib 24 mg with placebo, and reports a Cox proportional-hazard effect measure. The resulting hazard ratio is 0.21, with a 99% two-sided confidence interval of 0.14–0.31.
The most important statistical lesson is that the hazard ratio should not be read in isolation. The endpoint definition establishes what event is being measured; the ITT population establishes who contributes to the randomized comparison; the time-to-event framework accounts for event timing and censoring; the Cox model supplies the relative hazard estimate; and the confidence interval communicates uncertainty. The ClinicalTrials.gov record does not report a numerical p-value, so none is added here.